Received Nov 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 72R4G | — |
Shingrix administration with another diluent than the one provided; Shingrix administration with another diluent than the one provided; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number 72R4G, expiry date 05-JUN-2027) for prophylaxis. On 24-OCT-2025, the patient received Shingrix. On 24-OCT-2025, an unknown time after receiving Shingrix, the patient experienced wrong solution used in drug reconstitution (Verbatim: Shingrix administration with another diluent than the one provided) and inappropriate dose of vaccine administered (Verbatim: Shingrix administration with another diluent than the one provided). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 24-OCT-2025 The nurse manager wanted to know how to proceed with a patient that received the Shingrix reconstituted with the Merck's MMR diluent. The vaccine administration facility was the same as primary reporter.